分组1 - Oncternal Therapeutics reported a quarterly loss of $2.89 per share, which was better than the Zacks Consensus Estimate of a loss of $3.03, representing an earnings surprise of 4.62% [1] - The company posted revenues of $0.8 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 233.75%, compared to revenues of $0.11 million a year ago [2] - The stock has underperformed, losing about 46.5% since the beginning of the year, while the S&P 500 gained 9% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$3.04 on revenues of $0.24 million, and for the current fiscal year, it is -$11.63 on revenues of $1.28 million [7] - The Medical - Drugs industry is currently in the top 42% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates